menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

BIOR / Biora Therapeutics' (BIOR) CEO Adi Mohanty on Q1 2022 Results - Earnings Call Transcript

Biora Therapeutics' (BIOR) CEO Adi Mohanty on Q1 2022 Results - Earnings Call Transcript
Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Chuck Padala – Managing Director, LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d'Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Sahil Kazmi – B. Riley Securities Operator Welcome to the Biora Therapeutics First Quarter 2022 Earnings Call. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Biora

Therapeutics

BIOR

Mohanty

2022

Results

Earnings

Therapeutics

bior

Transcript

Stock

Posted: May 10 2022, 22:16
Author Name: Seeking Alpha
Views: 110743

BIOR News  

Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Chuck Padala - Managing Direc more_horizontal

Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update

By GlobeNewsWire
July 15, 2023

Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, to more_horizontal

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

By GlobeNewsWire
June 8, 2023

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, to more_horizontal

Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 15, 2023

Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Kristy Grabowski - IR Aditya Moh more_horizontal

Biora Therapeutics, Inc. (BIOR) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 30, 2023

Biora Therapeutics, Inc. (BIOR) Q4 2022 Earnings Call Transcript

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Chuck Padala – Managing Dire more_horizontal

Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?

By InvestorPlace
January 11, 2023

Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?

Biora Therapeutics (NASDAQ: BIOR ) stock is on the rise Wednesday following news of feedback from the FDA. Today's news concerns the company's Targete more_horizontal

Biora Therapeutics Stock Extend Surge on FDA Feedback

By Schaeffers Research
January 11, 2023

Biora Therapeutics Stock Extend Surge on FDA Feedback

Biora Therapeutics Inc   (NASDAQ:BIOR) is looking to extend yesterday's pop, last seen up 8.5% at $5.86. more_horizontal

Biora Therapeutics, Inc. (BIOR) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 14, 2022

Biora Therapeutics, Inc. (BIOR) Q3 2022 Earnings Call Transcript

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Alexandra Schuman - IR, Life more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: